Waters (WAT) Stock Could Be 15% Undervalued As Cash Flow Supports Value
Waters stock has delivered a strong 55.3% return over the past three years, yet the current checks send a mixed signal as the Discounted Cash Flow (DCF) intrinsic value points to upside while market based multiples look rich and the broader score leans expensive.
- Over the past three years, Waters has returned 55.3%, which puts more focus on whether the current share price already builds in much of the progress investors were looking for.
- Future cash flow growth from its analytical instruments and services can support the intrinsic value case. At the same time, any pressure on margins or slower cash flow conversion may challenge that view.
- The company scores 1 out of 6 on the broader valuation checks, which suggests Waters does not screen as a clear bargain on most measures even though the DCF points to it trading about 15.1% below intrinsic value.
For investors, the debate is whether Waters is still attractively valued after its multi year share price gains or whether the richer multiples and low overall value score leave less room for error.
Compare Waters' recent 33.6% 1 year gain and mixed valuation signals with hand picked opportunities in 47 high quality undervalued stocks that pair cash flow strength with solid balance sheets.
Does Waters Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model values Waters based on the cash it is expected to generate for shareholders. On the latest twelve month numbers, the company produced about $364.5 million of free cash flow, which the model projects as growing over time rather than shrinking. Using a 2 Stage Free Cash Flow to Equity approach, those projected cash flows support an estimated intrinsic value of about $482 per share.
That output compares with the current share price, which the model suggests is about 15.1% below this intrinsic value estimate. For investors considering Waters after a strong share price run, the DCF indicates that the cash flow profile still supports a case that the stock trades at a discount, even if other valuation checks screen it as expensive.
On this DCF view, Waters stock currently appears undervalued relative to its projected cash flows.
Our Discounted Cash Flow (DCF) analysis suggests Waters is undervalued by 15.1%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Is Waters Getting Expensive on Sales?
P/S is often a useful yardstick for Waters because the company is heavily focused on high value instruments and services, where revenue quality matters a lot. Waters currently trades on a P/S of about 8.7x, compared with a Life Sciences industry average of around 4.3x. It also sits above the peer group average of about 5.6x, which already reflects other companies with meaningful revenue bases.
The fair P/S ratio for Waters, which adjusts for its growth profile, margins, size and risk, is estimated at about 7.4x. That benchmark is lower than the current 8.7x level, which indicates that the stock carries a premium even after allowing for company specific strengths. Investors weighing Waters against other Life Sciences stocks may view this as a sign that the market is already pricing in a lot of positive expectations on the revenue side.
On the P/S multiple, Waters stock appears overvalued compared with both tailored and broad industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Waters Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Waters' valuation puzzle leaves off and spell out the specific growth, margin and earnings paths that would need to hold for the stock to be worth materially more or materially less than today’s price on the Community page. Each narrative connects its figures to a clear view on how Waters' growth, profitability and risks might develop, which you can revisit as new results and information emerge.
Community narratives on Waters are pulling in very different directions, which gives you two sharply contrasted paths to consider.
Bull case: 7% undervalued
"Waters is poised to benefit from robust growth in pharmaceutical R&D, evidenced by strong double-digit pharma segment expansion, increased instrument replacement cycles, and deeper penetration into high-growth areas like CDMOs and generics; this supports sustained revenue growth and pricing power as new product launches gain traction..."
Read the full Bull Case to see why Waters could be undervalued
Bear case: 14% overvalued
"Reliance on mature product lines and customer budget constraints may limit growth and erode long-term pricing power despite recent innovation and expansion efforts..."
Read the full Bear Case to see why Waters could be overvalued
Do you think there's more to the story for Waters? Head over to our Community to see what others are saying!
The Bottom Line
For Waters, the Discounted Cash Flow (DCF) work points to intrinsic value above the current share price, yet market based multiples suggest the stock is already priced at a premium to peers. That split reflects a cash flow profile that screens attractive while sentiment and comparisons to similar companies lean cautious. The broader checks are weak, so the intrinsic value signal on its own is not a clear green light. The key question from here is whether Waters can sustain cash flow that matches the intrinsic value case, or whether revenue growth and margins fall short and leave the higher multiple exposed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com